Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (291-300 of 315) with videos related to

Pageof 32
Sort By:
The Journal of Allergy and Clinical Immunology|June 14, 2023
Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatmentEric L Simpson, Patrick M Schlievert, Takeshi Yoshida, et al.
The New England Journal of Medicine|October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi ConsensusJamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.
Journal of the American Academy of Dermatology|March 18, 2019
Navigating the landscape of core outcome set development in dermatologyCecilia A C Prinsen, Phyllis I Spuls, Jan Kottner, et al.
The Journal of Allergy and Clinical Immunology|January 23, 2023
The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in miceBarbara Yang, Hazel Wilkie, Mrinmoy Das, et al.
The Journal of Investigative Dermatology|February 24, 2020
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)Joel M Gelfand, Daniel B Shin, Kristina Callis Duffin, et al.
JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Pageof 32

Showing results (291-300 of 315) with videos related to

Sort By:
Pageof 32
The Journal of Allergy and Clinical Immunology|June 14, 2023
Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatmentEric L Simpson, Patrick M Schlievert, Takeshi Yoshida, et al.
The New England Journal of Medicine|October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi ConsensusJamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.
Journal of the American Academy of Dermatology|March 18, 2019
Navigating the landscape of core outcome set development in dermatologyCecilia A C Prinsen, Phyllis I Spuls, Jan Kottner, et al.
The Journal of Allergy and Clinical Immunology|January 23, 2023
The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in miceBarbara Yang, Hazel Wilkie, Mrinmoy Das, et al.
The Journal of Investigative Dermatology|February 24, 2020
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)Joel M Gelfand, Daniel B Shin, Kristina Callis Duffin, et al.
JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
American Journal of Clinical Dermatology|September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 WeeksAlan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Pageof 32